Univariate analysis of lethal arrhythmic event during the follow-up of Brugada syndrome cohort-I
| Variables . | Hazard ratio (95% CI) . | P-value . |
|---|---|---|
| History of aborted cardiac arrest | 6.58 (3.94–10.97) | 5.3E-13 |
| LOF-SCN5A mutations | 3.18 (1.72–5.90) | 2.4E−04 |
| In silico–predicted rare SCN5A variants | 2.08 (1.12–3.84) | 0.02 |
| History of syncope (without aborted cardiac arrest) | 2.07 (0.92–4.69) | 0.08 |
| Male | 1.43 (0.20–10.34) | 0.72 |
| VT/VF by programmed electrical stimulation | 1.72 (0.98–3.02) | 0.06 |
| Family history of sudden cardiac deatha | 1.11 (0.56–2.18) | 0.77 |
| Documented atrial fibrillation | 1.83 (1.02–3.27) | 0.043 |
| Late potential positive | 1.50 (0.75–2.97) | 0.25 |
| Spontaneous type-I ST elevation | 1.34 (0.74–2.44) | 0.33 |
| QRS (V5) ≥ 120 ms | 2.57 (1.34–4.93) | 0.005 |
| P (II) ≥ 120 ms | 2.71 (1.53–4.80) | 0.001 |
| Variables . | Hazard ratio (95% CI) . | P-value . |
|---|---|---|
| History of aborted cardiac arrest | 6.58 (3.94–10.97) | 5.3E-13 |
| LOF-SCN5A mutations | 3.18 (1.72–5.90) | 2.4E−04 |
| In silico–predicted rare SCN5A variants | 2.08 (1.12–3.84) | 0.02 |
| History of syncope (without aborted cardiac arrest) | 2.07 (0.92–4.69) | 0.08 |
| Male | 1.43 (0.20–10.34) | 0.72 |
| VT/VF by programmed electrical stimulation | 1.72 (0.98–3.02) | 0.06 |
| Family history of sudden cardiac deatha | 1.11 (0.56–2.18) | 0.77 |
| Documented atrial fibrillation | 1.83 (1.02–3.27) | 0.043 |
| Late potential positive | 1.50 (0.75–2.97) | 0.25 |
| Spontaneous type-I ST elevation | 1.34 (0.74–2.44) | 0.33 |
| QRS (V5) ≥ 120 ms | 2.57 (1.34–4.93) | 0.005 |
| P (II) ≥ 120 ms | 2.71 (1.53–4.80) | 0.001 |
VF, ventricular fibrillation; VT, ventricular tachycardia; CI, confidence interval.
Prevalence at ≤45 years old.
Univariate analysis of lethal arrhythmic event during the follow-up of Brugada syndrome cohort-I
| Variables . | Hazard ratio (95% CI) . | P-value . |
|---|---|---|
| History of aborted cardiac arrest | 6.58 (3.94–10.97) | 5.3E-13 |
| LOF-SCN5A mutations | 3.18 (1.72–5.90) | 2.4E−04 |
| In silico–predicted rare SCN5A variants | 2.08 (1.12–3.84) | 0.02 |
| History of syncope (without aborted cardiac arrest) | 2.07 (0.92–4.69) | 0.08 |
| Male | 1.43 (0.20–10.34) | 0.72 |
| VT/VF by programmed electrical stimulation | 1.72 (0.98–3.02) | 0.06 |
| Family history of sudden cardiac deatha | 1.11 (0.56–2.18) | 0.77 |
| Documented atrial fibrillation | 1.83 (1.02–3.27) | 0.043 |
| Late potential positive | 1.50 (0.75–2.97) | 0.25 |
| Spontaneous type-I ST elevation | 1.34 (0.74–2.44) | 0.33 |
| QRS (V5) ≥ 120 ms | 2.57 (1.34–4.93) | 0.005 |
| P (II) ≥ 120 ms | 2.71 (1.53–4.80) | 0.001 |
| Variables . | Hazard ratio (95% CI) . | P-value . |
|---|---|---|
| History of aborted cardiac arrest | 6.58 (3.94–10.97) | 5.3E-13 |
| LOF-SCN5A mutations | 3.18 (1.72–5.90) | 2.4E−04 |
| In silico–predicted rare SCN5A variants | 2.08 (1.12–3.84) | 0.02 |
| History of syncope (without aborted cardiac arrest) | 2.07 (0.92–4.69) | 0.08 |
| Male | 1.43 (0.20–10.34) | 0.72 |
| VT/VF by programmed electrical stimulation | 1.72 (0.98–3.02) | 0.06 |
| Family history of sudden cardiac deatha | 1.11 (0.56–2.18) | 0.77 |
| Documented atrial fibrillation | 1.83 (1.02–3.27) | 0.043 |
| Late potential positive | 1.50 (0.75–2.97) | 0.25 |
| Spontaneous type-I ST elevation | 1.34 (0.74–2.44) | 0.33 |
| QRS (V5) ≥ 120 ms | 2.57 (1.34–4.93) | 0.005 |
| P (II) ≥ 120 ms | 2.71 (1.53–4.80) | 0.001 |
VF, ventricular fibrillation; VT, ventricular tachycardia; CI, confidence interval.
Prevalence at ≤45 years old.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
